T. Rowe Price Associates’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

T. Rowe Price Associates’s Portfolio EUCRW Stock Details EUCRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-22,697	Closed	-$1K	–	3033
2023 Q1	$1K	Hold	22,697	–	–	﹤0.01%	2922
2022 Q4	$1K	Hold	22,697	–	–	﹤0.01%	2932
2022 Q3	$1K	Hold	22,697	–	–	﹤0.01%	2949
2022 Q2	$2K	Hold	22,697	–	–	﹤0.01%	2955
2022 Q1	$4K	Hold	22,697	–	–	﹤0.01%	2971
2021 Q4	$13K	Hold	22,697	–	–	﹤0.01%	2969
2021 Q3	$18K	Hold	22,697	–	–	﹤0.01%	2933
2021 Q2	$24K	Buy	22,697 +6,766	+42%	+$6.07K	﹤0.01%	2912
2021 Q1	$14K	Buy	+15,931	New	+$25.8K	﹤0.01%	2841

T. Rowe Price Associates's EUCRW Position: Q2 2023 in Review

T. Rowe Price Associates sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q2 2023, closing a stake of 22,697 shares — an estimated $1K sold.

T. Rowe Price Associates first reported a position in EUCRW in Q1 2021 and held it in 9 quarters. The position peaked at $24K in Q2 2021. 0 funds tracked by Wall St. Rank hold EUCRW as of Q2 2023.

T. Rowe Price Associates reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q2 2023 after selling out during the quarter.
T. Rowe Price Associates sold 22,697 Eucrates Biomedical Acquisition Corp. Warrant shares in Q2 2023, an estimated $1K.
T. Rowe Price Associates first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q1 2021 and held it in 9 quarters.
T. Rowe Price Associates's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $24K in Q2 2021.
0 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q2 2023.

Based on T. Rowe Price Associates's 13F filing for Q2 2023, filed 14 Aug 2023.